Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.4%

7 terminated/withdrawn out of 109 trials

Success Rate

92.8%

+6.3% vs industry average

Late-Stage Pipeline

16%

17 trials in Phase 3/4

Results Transparency

14%

13 of 90 completed trials have results

Key Signals

5 recruiting13 with results6 terminated

Enrollment Performance

Analytics

Phase 1

66(62.9%)

Phase 2

21(20.0%)

Phase 3

14(13.3%)

Phase 4

3(2.9%)

N/A

1(1.0%)

105Total

Phase 1(66)

Phase 2(21)

Phase 3(14)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (109)

Showing 20 of 109 trials

NCT07555743Phase 4Not Yet Recruiting

Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia

Role: collaborator

NCT05924425Phase 4Recruiting

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Role: collaborator

NCT07532252Phase 2Not Yet Recruiting

Daridorexant for Alcohol Use Disorder

Role: collaborator

NCT05423717Phase 2Completed

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Role: lead

NCT07212101Not ApplicableCompleted

Sleep in Collegiate Baseball Players

Role: collaborator

NCT06498128Recruiting

Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

Role: lead

NCT03737214Phase 3Active Not Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Role: lead

NCT05948579Phase 2Not Yet Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone

Role: collaborator

NCT05948540Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Role: collaborator

NCT05948553Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Role: collaborator

NCT06816433Phase 2Not Yet Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

Role: collaborator

NCT05422612Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Role: collaborator

NCT06393504Active Not Recruiting

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Role: lead

NCT02944474Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects

Role: lead

NCT02944487Phase 1Completed

A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects

Role: lead

NCT05597020Phase 4Completed

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

Role: lead

NCT06311864Enrolling By Invitation

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

Role: collaborator

NCT06799884Phase 1Completed

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

Role: lead

NCT03425539Phase 3Completed

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

Role: lead

NCT03585270Phase 3Completed

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain

Role: lead